{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-066932","form_type":"8-K","ticker":"TECX","cik":"0001681087","company_name":"Tectonic Therapeutic, Inc.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.317624+00:00","generated_at":"2026-05-22T04:50:58.980904+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Tectonic Q1 net loss $15.9M; cash $306M; TX45 Phase 1b shows PCWP reduction 17.9%","bullets":["Net loss of $15.9M for Q1 2025 vs $15.2M in Q1 2024; R&D expenses $13.0M, G&A $5.3M.","Cash and equivalents $306.2M as of Mar 31, 2025, providing runway into Q4 2028; $185M PIPE closed Feb 2025.","TX45 Phase 1b Part A: 17.9% reduction in PCWP in PH-HFpEF; >30% PVR reduction in CpcPH subgroup.","Full Phase 1b Part A data to be presented May 17, 2025 at ESC Heart Failure Congress.","Part B of TX45 Phase 1b (PH-HFrEF) enrolling; topline expected 2H 2025; APEX Phase 2 data expected 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-066932","json":"https://secwatch.observer/filing/0000950170-25-066932.json","markdown":"https://secwatch.observer/filing/0000950170-25-066932.md","text":"https://secwatch.observer/filing/0000950170-25-066932.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1681087/000095017025066932/0000950170-25-066932-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1681087/000095017025066932/tecx-20250508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T04:50:58.980904+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}